Today's Top Performers In Drugs

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 67 points (-0.4%) at 17,031 as of Tuesday, Sept. 2, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,211 issues advancing vs. 1,801 declining with 159 unchanged.

The Drugs industry currently sits down 0.5% versus the S&P 500, which is down 0.3%. A company within the industry that fell today was Novo Nordisk A/S ( NVO), up 1.4%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Regeneron Pharmaceuticals ( REGN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Regeneron Pharmaceuticals is up $12.79 (3.6%) to $363.24 on heavy volume. Thus far, 915,749 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 814,100 shares. The stock has ranged in price between $362.38-$369.31 after having opened the day at $367.00 as compared to the previous trading day's close of $350.46.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $34.7 billion and is part of the health care sector. Shares are up 27.3% year-to-date as of the close of trading on Friday. Currently there are 8 analysts who rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, solid stock price performance and growth in earnings per share. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Regeneron Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Valeant Pharmaceuticals International ( VRX) is up $1.71 (1.5%) to $119.01 on light volume. Thus far, 969,943 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 2.9 million shares. The stock has ranged in price between $116.67-$119.50 after having opened the day at $117.28 as compared to the previous trading day's close of $117.30.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. Valeant Pharmaceuticals International has a market cap of $39.3 billion and is part of the health care sector. Shares are down 0.1% year-to-date as of the close of trading on Friday. Currently there are 9 analysts who rate Valeant Pharmaceuticals International a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in stock price during the past year and increase in net income. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and disappointing return on equity. Get the full Valeant Pharmaceuticals International Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Gilead ( GILD) is up $1.46 (1.4%) to $109.02 on average volume. Thus far, 7.0 million shares of Gilead exchanged hands as compared to its average daily volume of 12.0 million shares. The stock has ranged in price between $107.61-$109.50 after having opened the day at $108.17 as compared to the previous trading day's close of $107.56.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $162.6 billion and is part of the health care sector. Shares are up 43.2% year-to-date as of the close of trading on Friday. Currently there are 13 analysts who rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Gilead Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Stocks Lose Steam as Yields Hover Near 3% Threshold

Stocks Lose Steam as Yields Hover Near 3% Threshold

Video: Stop Using Student Loan Money to Buy Bitcoin

Video: Stop Using Student Loan Money to Buy Bitcoin

Let the Najarian Brothers Crash-Proof Portfolio

Let the Najarian Brothers Crash-Proof Portfolio

Facebook Sends Facial Recognition Notification in Error

Facebook Sends Facial Recognition Notification in Error

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists